Related Experiment Videos
Current pharmacotherapy for Alzheimer's disease
A Lleó1, S M Greenberg, J H Growdon
1Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Annual Review of Medicine
|January 18, 2006
Summary
Alzheimer's disease treatments focus on increasing acetylcholine levels or blocking NMDA receptors for symptomatic relief. Current drugs do not alter the underlying neurodegenerative process of Alzheimer's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Geriatrics
Background:
- Alzheimer's disease (AD) is a prevalent age-related neurodegenerative disorder affecting millions.
- Current pharmacotherapy for AD primarily targets cholinergic neurotransmission.
- Existing treatments offer symptomatic benefits but do not halt disease progression.
Purpose of the Study:
- To review current pharmacotherapies for Alzheimer's disease.
- To discuss the mechanisms of action and limitations of existing AD drugs.
- To highlight the need for neuroprotective agents in AD treatment.
Main Methods:
- Review of FDA-approved medications for Alzheimer's disease.
- Analysis of the pharmacological targets and clinical efficacy of acetylcholinesterase inhibitors (AChEIs) and memantine.
- Discussion of the pathophysiology of dementia in AD.
Main Results:
- Acetylcholinesterase inhibitors (AChEIs) were FDA-approved starting in 1995 for symptomatic benefit.
- Memantine, an NMDA antagonist, was approved in 2004 for moderate to severe AD.
- Neither AChEIs nor memantine, alone or in combination, modify the underlying neurodegeneration in AD.
Conclusions:
- Current AD pharmacotherapies provide symptomatic relief but do not address the core pathology.
- Dementia in AD stems from progressive synaptic loss and neuronal death.
- Future therapeutic strategies aim to develop neuroprotective drugs to slow or prevent neuronal damage in Alzheimer's disease.